Evidence map›Paper›PMID 28923117›Full record

ArticleParasites & vectors2017

Efficacy of fluralaner (Bravecto™ chewable tablets) for the treatment of naturally acquired Linognathus setosus infestations on dogs.

Heike Kohler-Aanesen, Seppo Saari, Rob Armstrong, Karine Péré, Janina Taenzler, Eva Zschiesche, Anja R Heckeroth

Abstract readComparative Study
In one paragraph

Article in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Successful treatment of 3 naturally acquired cases of canine cheyletiellosis with fluralaner.The Canadian veterinary journal = La revue veterinaire canadienne · 2024
    Article
  4. Fluralaner (BravectoParasites & vectors · 2023
    Article
  5. Isoxazolines for treating canine demodicosis, sarcoptic mange (scabies), and lice infestation.The Canadian veterinary journal = La revue veterinaire canadienne · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Oral fluralaner as a treatment forThe Canadian veterinary journal = La revue veterinaire canadienne · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Heike Kohler-AanesenMSD Animal Health Norge AS, Thormøhlensgate 55, 5008, Bergen, Norway.
Seppo SaariMSD Animal Health, Keilaranta 3, 02150, Espoo, Finland.
Rob ArmstrongMerck Animal Health, 2 Giralda Farms, Madison, NJ, 07940-1026, USA.
Karine PéréMSD Animal Health Innovation SAS, 7, rue Olivier de Serres, Angers Technopole CS67131, 49071, Beaucouzé, France.
Janina TaenzlerMSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany. janina.taenzler@msd.de.
Eva ZschiescheMSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany.
Anja R HeckerothMSD Animal Health Innovation GmbH, Research Antiparasitics, Zur Propstei, 55270, Schwabenheim, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical efficacy of fluralaner chewable tablets (Bravecto™, MSD Animal Health) against naturally acquired Linognathus setosus infestations on dogs was evaluated compared with permethrin (Exspot®, MSD Animal Health) treatment.

methodsPrivately-owned dogs naturally infested with L. setosus from 21 different households were randomly allocated to two treatment groups. Fourteen dogs were treated once orally with fluralaner and ten dogs were treated once topically with permethrin, at the recommended label dose. Live L. setosus on all dogs were counted before treatment and 1, 7, 28 (both groups) and 84 (fluralaner group) days post-treatment according to a coat parting technique at pre-specified locations and lice species were confirmed microscopically. At the same time points, a veterinary dermatology severity score and an owner's perceived pruritus score were recorded.

resultsPercentage reduction in geometric mean L. setosus counts, comparing post- with pre-treatment counts within each group, were 85.7% (day 1), 96.8% (day 7) and 100% (days 28 and 84) for the fluralaner (two-sided two-sample t-test, P ≤ 0.0088 for days 1-84) and 67.5% (day 1), 90.3% (day 7) 99.1% (day 28) for the permethrin group (two-sided two-sample t-test, P ≤ 0.0014 for days 7-28). No lice were seen on fluralaner-treated dogs 28 and 84 days post-treatment. In contrast, two permethrin-treated dogs were re-treated at 7 and 28 days after initial treatment because of observed lice. Owner's perceived pruritus scores were reduced compared to pre-treatment levels by 23.8% (day 1), 31.1% (day 7), 70.4% (day 28) and 99.5% (day 84) after fluralaner treatment and 21.3% (day 1), 45.8% (day 7), and 78.1% (day 28) after permethrin treatment. Dermatological signs were improved compared to pre-treatment levels in both treatment groups.

conclusionsSingle oral fluralaner treatment eliminated natural L. setosus infestation on dogs within 28 days and led to complete dermatological recovery that was maintained until the study end on day 84. Single topical permethrin treatment reduced the number of L. setosus by 99.1% at day 28 although two animals required unscheduled re-treatment.

Indexed as

Administration, OralAdministration, TopicalAnimalsAnopluraDog DiseasesDogsFemaleInsecticidesIsoxazolesLice InfestationsMalePermethrinRandom AllocationTabletsTreatment OutcomeA1443 compoundInsecticidesIsoxazolesPermethrinTabletsBravecto™Chewable tabletsDogEfficacyExspot®FluralanerLiceLinognathus setosusOralPermethrinTopical

Identifiers

PMID28923117
PMCPMC5604360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.